Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts

Clin Infect Dis. 2010 May 1;50(9):1252-5. doi: 10.1086/651605.

Abstract

Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for the H275Y resistance mutation during therapy in 2 immunocompromised individuals at 9 and 14 days of therapy, as well as the first described case of clinically significant resistance to peramivir.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acids, Carbocyclic
  • Amino Acid Substitution / genetics
  • Antiviral Agents / pharmacology*
  • Cyclopentanes / pharmacology*
  • Drug Resistance, Viral*
  • Female
  • Guanidines / pharmacology*
  • Humans
  • Immunocompromised Host
  • Influenza A Virus, H1N1 Subtype / drug effects*
  • Influenza A Virus, H1N1 Subtype / genetics
  • Influenza A Virus, H1N1 Subtype / isolation & purification
  • Influenza, Human / drug therapy*
  • Influenza, Human / virology*
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Mutation, Missense
  • Oseltamivir / pharmacology*
  • RNA, Viral / genetics
  • Selection, Genetic
  • Sequence Analysis, DNA
  • Young Adult

Substances

  • Acids, Carbocyclic
  • Antiviral Agents
  • Cyclopentanes
  • Guanidines
  • RNA, Viral
  • Oseltamivir
  • peramivir

Associated data

  • GENBANK/GU571152
  • GENBANK/GU571153
  • GENBANK/GU571154
  • GENBANK/GU571155
  • GENBANK/GU571156